MYOSIN THERAPEUTICS INC.

JUPITER, FL

Oncologysmall moleculeGrant-only

What changed

NIH SB1 · $0.2M · Development of drug product to support a Phase 0/1b dose escalation trial of MT-125 in recurrent high grade gliomas

10mo agoNew grantSep 16, 2025Source filing (opens the source filing in a new tab)

Momentum

41no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
SB1 · $249k · non-dilutive
Sep 1, 2025
MYOSIN THERAPEUTICS INC. · PI BROWNSTEIN, MICHAEL J · NCI · award ends Aug 31, 2026 · Development of drug product to support a Phase 0/1b dose escalation trial of MT-125 in recurrent high grade gliomas
NIH RePORTER · NIH RePORTER 11183035 (opens the source filing in a new tab)
Grant
R42 · $911k · non-dilutive
Apr 1, 2023
MYOSIN THERAPEUTICS INC. · PI ROSENFELD, STEVEN S · NCI · award ends Dec 31, 2025 · MT-125 for the Therapeutic Treatment of Glioblastoma
NIH RePORTER · NIH RePORTER 11012345 (opens the source filing in a new tab)
Grant
R44 · $2.2M · non-dilutive
Apr 1, 2023
MYOSIN THERAPEUTICS INC. · PI BROWNSTEIN, MICHAEL J · NCI · award ends Jul 31, 2027 · Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas
NIH RePORTER · NIH RePORTER 11174970 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 1.00name similarity 100% · semantic similarity 96% · shared principal investigator / founder · same city · same therapeutic area
Semantic similarity of the underlying science links the grant record at 0.87name similarity 100% · semantic similarity 98% · same city · same therapeutic area
new_entity links the grant record at 0.26same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH SB1 · $0.2M · Development of drug product to support a Phase 0/1b dose escalation trial of MT-125 in recurrent high grade gliomas
10mo agoNew grantSource (opens the source filing in a new tab)
NIH R44 · $2.2M · Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas
11mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R42 · $0.9M · MT-125 for the Therapeutic Treatment of Glioblastoma
Jan 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

SB1 · $249k · non-dilutive

R42 · $911k · non-dilutive

R44 · $2.2M · non-dilutive